A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder.
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 28 Aug 2006 Status change
- 28 Aug 2006 The expected completion date for this trial is now .
- 03 Dec 2005 New trial record.